A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors

被引：0
|
作者：
Baird, Richard D.
Papa, Sophie
Cresti, Nicola
Hatcher, Helen
Hogarth, Linda
Jamal-Hanjani, Mariam
Frenkel, Eugene P.
Donaldson, Kirsteen
Posner, John
Kawabata, Izumi
Jodrell, Duncan Ian
Plummer, Ruth
Spicer, James F.
机构：
[1] Univ Cambridge, Dept Oncol, Cambridge, England
[2] Kings Coll London, London WC2R 2LS, England
[3] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[5] Shionogi & Co Ltd, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3100
引用
收藏
页数：1
相关论文
共 50 条
  • [41] BIBW-2992 Dual EGFR/HER2 Inhibitor Oncolytic
    Campas, C.
    Castaner, R.
    Bolos, J.
    DRUGS OF THE FUTURE, 2008, 33 (08) : 649 - 654
  • [42] Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
    Bahleda, Rastislav
    Varga, Andrea
    Berge, Yann
    Soria, Jean-Charles
    Schnell, David
    Tschoepe, Inga
    Uttenreuther-Fischer, Martina
    Delord, Jean-Pierre
    BRITISH JOURNAL OF CANCER, 2018, 118 (03) : 344 - 352
  • [43] Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
    Rastislav Bahleda
    Andrea Varga
    Yann Bergé
    Jean-Charles Soria
    David Schnell
    Inga Tschoepe
    Martina Uttenreuther-Fischer
    Jean-Pierre Delord
    British Journal of Cancer, 2018, 118 : 344 - 352
  • [44] Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
    Montemurro, Filippo
    Valabrega, Giorgio
    Aglietta, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 257 - 268
  • [45] A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors.
    Saka, Wasiru Olugbenga
    Pacey, Simon
    Blackhall, Fiona Helen
    Garcia-Corbacho, Javier
    Fusi, Alberto
    Karydis, Ioannis
    Hategan, Mirela
    Laviste, Glenda
    Halford, Sarah E. R.
    Foxton, Caroline
    McLeod, Robert
    Wan, Susan
    Talbot, Denis Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
    Kim, Hwang-Phill
    Yoon, Young-Kwang
    Kim, Jin-Won
    Han, Sae-Won
    Hur, Hyung-Seok
    Park, Jinah
    Lee, Ju-Hee
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Kim, Tae-You
    PLOS ONE, 2009, 4 (06):
  • [47] A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)
    Wakelee, H. A.
    Fehling, J. M.
    Molina, J. R.
    Lensing, J. L.
    Funke, R. P.
    Miles, D.
    Sikic, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [49] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [50] Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
    Garland, LL
    Pegram, M
    Song, S
    Mendelson, D
    Parker, KE
    Martell, RE
    Gordon, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 229S - 229S
12345